Abstract
AbstractThe mRNA‐1273 vaccine for coronavirus disease (COVID‐19) authorised as one of the first COVID‐19 vaccines was released by Moderna in December 2020. A recent study indicates that messenger RNA (mRNA) vaccines appear to be effective in preventing aggravation, hospitalisation and death against COVID‐19 infection. However several adverse effects have been reported. Of these, the dermatological adverse effects are relatively rare entities Herein, we present a case of inflammatory disseminated superficial porokeratosis exacerbated after administration of the fourth dose of the mRNA‐1273 vaccine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
